Liquidia (NASDAQ:LQDA) Director Sells 145,954 Shares

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 145,954 shares of the business’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $65.58, for a total value of $9,571,663.32. Following the sale, the director owned 1,418,453 shares in the company, valued at approximately $93,022,147.74. This trade represents a 9.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Liquidia Trading Down 0.6%

NASDAQ LQDA traded down $0.40 during trading hours on Friday, reaching $71.23. The company’s stock had a trading volume of 1,693,791 shares, compared to its average volume of 1,738,461. The firm has a fifty day simple moving average of $49.18 and a 200-day simple moving average of $40.67. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. Liquidia Corporation has a 52 week low of $11.85 and a 52 week high of $72.71. The stock has a market cap of $6.33 billion, a P/E ratio of 508.82 and a beta of 0.58.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.11. The firm had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm’s revenue for the quarter was up 4187.1% on a year-over-year basis. Equities analysts forecast that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Wall Street Zen raised Liquidia from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 16th. Zacks Research raised Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. HC Wainwright raised their price objective on Liquidia from $67.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday, June 5th. Needham & Company LLC lifted their price objective on Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Finally, Oppenheimer set a $75.00 target price on Liquidia in a report on Friday, June 5th. Three research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $60.29.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Apis Capital Advisors LLC purchased a new stake in shares of Liquidia during the 3rd quarter worth approximately $9,569,000. Farallon Capital Management LLC lifted its stake in Liquidia by 102.1% in the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after purchasing an additional 4,326,876 shares during the last quarter. GSA Capital Partners LLP grew its holdings in Liquidia by 63.6% during the fourth quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock valued at $2,179,000 after purchasing an additional 24,555 shares during the period. Tudor Investment Corp ET AL purchased a new stake in Liquidia in the third quarter worth $1,536,000. Finally, State of New Jersey Common Pension Fund D purchased a new stake in Liquidia in the fourth quarter worth $709,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).